Home>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>Deoxypseudouridine

Deoxypseudouridine

Catalog No.GC33494

Deoxypseudouridine is a nucleoside analog.

Products are for research use only. Not for human use. We do not sell to patients.

Deoxypseudouridine Chemical Structure

Cas No.: 39967-60-7

Size Price Stock Qty
10mM (in 1mL DMSO)
$201.00
In stock
1mg
$101.00
In stock
5mg
$304.00
In stock
10mg
$506.00
In stock
25mg
$1,011.00
In stock
50mg
$1,440.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Deoxypseudouridine is a nucleotide analog.

Deoxypseudouridine is a nucleotide analog. Ethidium bromide staining of the gel demonstrates that the digestion of carrier DNA in both control and analog DNA samples (including Deoxypseudouridine) occur to the same extent; this indicates that the restriction enzyme is as active in the presence of the modified DNA substrate (including Deoxypseudouridine) as it is in the presence of unmodified (control) DNA. Enzymes that do not contain an AT base pair in their recognition sequence, restrict DNAs substituted with either deoxypseudouridine or deoxytubercidin as efficiently as control[1].

[1]. Bodnar JW, et al. Effect of nucleotide analogs on the cleavage of DNA by the restriction enzymes AluI, DdeI, HinfI, RsaI, and TaqI. J Biol Chem. 1983 Dec 25;258(24):15206-13.

Reviews

Review for Deoxypseudouridine

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Deoxypseudouridine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.